The molecular mechanism underlying epidermal growth factor receptor (EGFR) localization in mitochondria remains largely unknown. Using immune electron microscopy, we validated that EGFR could be localized on either the outer or the inner membrane of mitochondria. Mutant receptor lacked amino acids 646-660 was flawed in migration onto the organelles, whereas the mutated receptor with a defective endocytosis showed a greater capability of moving onto mitochondria upon stimulation of epidermal growth factor (EGF). Gefitinib, an inhibitor of EGFR kinase, inhibited the receptor endocytosis after short time of treatment, yet, only reduced cell viability as well as the amount of mitochondrial EGFR after longer time of exposure. Moreover, the content of mitochondrial EGFR transfer was decreased when the cells were exposed to the apoptotic inducer etoposide. EGF-induced programmed cell death usually coincided with a decline in mitochondrial EGFR. These data indicated that the mitochondrial-localized EGFR is independent of its internalization and may be correlated with cell survival and participate in the ligand-induced programmed cell death.
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Introduction
Binding of epidermal growth factor (EGF) to EGF receptor (EGFR) triggers the receptor dimerization, activates the tyrosine kinase, brings on the phosphorylation of the tyrosine residues of the receptor, and causes an array of signaling events [1, 2] . These events occurring on the plasma membranes ultimately lead to an alteration of gene expression in the nucleus. Besides the generation of multiple signal transduction events, the activation of EGFR by ligand also dramatically changes the cellular localization of receptors by accelerating internalization of EGFR through clathrin-dependent and -independent endocytic pathways [2] . The internalized ligand-receptor complexes accumulate in early endosomes from where they are either recycled back to the cell surface or targeted to the late endosomal and lysosomal compartments for degradation. Accelerated internalization and degradation of activated EGFR result in down-regulation of EGFR protein levels and attenuation of growth receptor signaling. Endocytosis also controls subcellular localization of activated receptors and their signaling complexes [3, 4] .
EGFR has also been found in caveoli, Golgi, endoplasmic reticulum, lysosome-like structures, nuclear envelopes, and nuclei [5, 6] . Recently, EGFR was found within mitochondria [7] . Boerner et al. revealed that EGFR translocated to mitochondria through interaction with proteins such as cytochrome c oxidase (Cox) subunit II. Our previous study also revealed that mitochondrially localized EGFR was subjected to be regulated by autophagic process [8] . Nevertheless, it is still unclear whether the mitochondrial transfer of EGFR is related with its endocyosis. Although EGFR is known to regulate cell proliferation, growth, and survival both in vivo and in vitro, it is apparent that EGF can activate the apoptotic program in cells expressing high quantities of the receptor [9, 10] . More recently, it was found that the function of
kinase-independent EGFR could prevent autophagic cell death by maintaining the intracellular glucose level through stabilization of the sodium/glucose co-transporter 1 [11] .
Mitochondrion is involved in a variety of cellular processes including proliferation, reactive oxygen species production, programmed cell death execution, and signal transduction [12 -14] . Growing evidence reveals that there exists an integrated signal system to coordinate the various molecular messages that enter and exit the mitochondrion according to the diverse needs of the cell [15] [16] [17] . Proteins, such as protein kinases, protein phosphatases, and even transcriptional factors, which are not conventionally mitochondrial resident members, are revealed to have a mitochondrial location [13, 16] .
Suppression of the EGFR expression by siRNA or inhibition of EGFR kinase activity by agent, such as gefitinib, can be effective in the treatment of certain cancer cell types [18] [19] [20] [21] . However, the molecular mechanisms underpinning any anti-tumor activity of EGFR repression have not been fully elucidated. Our data for the first time revealed that mitochondrial location of EGFR was independent of the receptor endocytosis and that gefitinib decreased cell viability as well as the quantity of mitochondrial EGFR. In addition, the programmed cell death triggered by EGF stimulation or etoposide treatment accompanied by a decline in mitochondrial EGFR.
Materials and Methods

Chemicals and antibodies
Mouse monoclonal anti-mitochondrial heat shock protein 70 (mtHsp70; MA3-28) and polyclonal rabbit antibody to EGFR (PA1-1110), early endosomal antigen 1 (EEA-1, PA1-063A), were purchased from Affinity Bioreagents (Golden, USA). Polyclonal antibodies of b-actin (A2066), etoposide were purchased from Sigma-Aldrich (St Louis, USA), and EGF conjugated to rhodamine (EGF-Rh), antibody to Cox IV (subunit IV, A6401), was from Molecular Probes (Eugene, USA). Mouse EGF was from Collaborative Research Inc. (Bedford, USA).
Plasmid construction
The full-length cDNA of mouse Cox7a2 was cloned into pEYFP-N1 (Clontech, Palo Alto, USA). Site-directed mutagenesis of EGFR was carried out using QuikChange Site-Directed Mutagenesis Kit according to the manufacture's protocol (Stratagene, La Jolla, USA).
Cell culture and transfection
Porcine aortic endothelial (PAE) cell lines stably expressing various mutated EGFR and green fluorescence-tagged protein (GFP) EGFR were described previously [22, 23] . Stable cell line expressing GFP-EGFR mutant in which amino acids 946-960 were deleted was kindly provided by Dr Francesc Tebar (Universitat de Barcelona, Barcelona, Spain). These cell lines were grown in Dulbecco's modified eagle medium (DMEM)/F12 media supplemented with 10% fetal bovine serum (FBS), antibiotics, glutamine, and G418 selection agent. Effectene Transfection Reagent Kit (Qiagen, Valencia, USA) was used for transient transfection. EGF treatments were carried out in a complete medium unless mentioned otherwise. Human epidermoid carcinoma A431 cells were grown in DMEM containing 10% FBS, antibiotics, and glutamine. All the cell lines were provided by Dr Sorkin (UCHCC, USA)
Subcellular fractionation
Mitochondria extraction has been done as described previously [8] . Briefly, cells were seeded into 150-mm dishes, with or without treatment (in full-serum medium). The cells were gathered, pelleted and washed three times with cold PBS. Cells were resuspended in homogenization buffer A (20 mM Hepes-KOH, pH 7.5, 250 mM sucrose, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM ethylene glycol tetraacetic acid, 1 mM ethylene diamine tetraacetic acid, 1 mM dithiothreitol, plus inhibitor) for 30-60 min, and subsequently homogenized at 6 Â 10 6 cells/ml in 500 ml buffer A (the amount of cells from different treatments for fractionation are always adjusted to the same level) by passing through a 25-G syringe needle on ice for 60 times. The homogenate was centrifuged at 1000 g for 15 min at 48C. The resulting supernatant A was collected, and the pellet was washed twice with buffer A without sucrose, saved as the nuclear fraction. Supernatant A was centrifuged at 12,000 g for 15 min at 48C. The resulting supernatant B was saved and ultra-centrifuged at 100,000 g for 40 min at 48C. Following ultra-centrifugation, the supernatant was collected as the cytosolic S100 (Cyt/S100) fraction and the pellet was labeled as the vesicular pellet. The pellet from supernatant A was washed two times with buffer A and labeled as the heavy mitochondrial membrane pellet (Hmmbp). This pellet (Hmmbp) was overlaid on a two-step sucrose density gradient as described elsewhere [24] and ultra-centrifuged at 60,000 g for 20 min at 48C. The pellet was washed twice with buffer A (P-Mito). All the subcellular fractions were preserved at 2808C until further analysis.
Proteinase K treatment
The mitochondrial fractions were treated with 100 ng/ml proteinase K (Invitrogen) in buffer A without protease inhibitors at room temperature for 30 min. The reaction was stopped by the addition of 1 mM phenylmethylsulfonyl fluoride and was analyzed by western blot analysis using the indicated antibodies.
Mitochondrial EGFR and endocytosis
Western blot analysis The cells and pellets of subcellular fraction were lysed in Triton X-100/glycerol solubilization buffer as described previously [25] , resolved on sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes. Western blot analysis was carried out with several antibodies followed by detection using the enhanced chemiluminescence system (Thermo Scientific, Rockford, USA).
Fluorescence microscopy
The fluorescence imaging workstation consisting of a Nikon inverted microscope was reported before [25] . Immunofluorescence staining was carried out with the indicated antibodies as described previously [25] . Briefly, PAE cells stably expressing GFP-EGFR were permeabilized and immunostained with anti-mtHsp70 antibody, followed by Cy3-labeled secondary antibody that allowing imaging. All images were finally processed using Adobe Photoshop (Adobe System, Mountain View, USA).
Immune electron microscopy Immune electron microscopy was carried out as described previously [8] . Briefly, A431 cells were fixed with 2% paraformaldehyde, subsequently dehydrated, embedded, and polymerized under UV light at room temperature for 48-72 h. Ultrathin sections were cut and collected on pioloform-coated nickel grids to continue the immunolabeling experiments.
Following pre-incubation in 1 Â PBS ( pH 7.4) containing 2% bovine serum albumen (BSA) for 10 min, the sections were incubated with the rabbit polyclonal antibody against EGFR (diluted 1:50 with 1 Â PBS containing 1% BSA) at 48C in a moist chamber overnight. After washing, the sections were placed on a drop of goat anti-rabbit secondary antibody conjugated to 10-nm colloidal gold particles (diluted 1:40 in 1 Â PBS, pH 8.2) at room temperature for 2 h. The dried sections were then stained with sodium acetate and observed under a transmission electron microscope.
Internalization of 125 I-EGF
125
I-EGF internalization experiments were carried out as described previously [23] . Briefly, PAE cells [expressing wild type (WT) or mutated EGFR] were incubated with 125 I-EGF (1 ng/ml) in binding media for 6 min at 378C, and the ratio of internalized to surface radioactivity was determined. The specific activity of 125 I-EGF was 1.5-2.0 Â 10 5 cpm/ng.
Cell proliferation assay A431 cells were plated in 96-well plates (4000 cells/well) in 100 ml complete culture medium. After overnight culture, cells were incubated with either drug-free or gefinitib (or etoposide) containing complete medium for indicated time periods, and the cellular viability was determined with Cell Titer 96 Aqueous Nonradioactive Cell Proliferation Assay Kit (Promega, Madison, USA).
Flow cytometry assay A431 cells were treated with 100 ng/ml EGF for 30 min, trypsinized and harvested, washed with PBS buffer followed by incubating with a fluorescein isothiocyanatelabeled annexin V (Cy5) and staining with propidium iodide (PI; Molecular Probes). Percentages of cells with annexin V positive and PI-negative staining were determined by flow cytometry.
Results
EGFR is associated with mitochondria
To investigate the localization of EGFR within mitochondria, immune electron microscopy, a method which is considered to be the most convincible approach to examination of the subcellular ultra-structure [26, 27] , was preformed in A431 cells and isolated mitochondria of the cells. The micrographs of electron microscopy clearly showed that EGFR labeled with gold particles were seen within the mitochondria (arrows), and no staining of colloidal gold was found in the negative control sample [ Fig. 1(A) ]. To further confirm the specificity of the immunogold labeling, mitochondria-enriched preparations from A431 cells were used. As shown in Fig. 1(B) , EGFR could locate either peripherally (white arrow) or inside mitochondria (black arrow), whereas no labeling was seen in the control sample. As the positive control, we used an antibody against the mtHsp70, a mitochondrial matrix protein involved in protein translocation into the mitochondria. To examine whether the receptor located on the plasma membrane can migrate into the organelles, EGF-Rh was utilized in following experiments. It revealed that EGF-Rh was co-localized with Cox7a2 (a subunit of the fourth complex in the mitochondrial respiratory chain) in YFP-Cox7a2 transfected mouse fibroblasts B82 cell which had a stable expression of EGFR. And the co-localization between EGF-Rh and Cox7a2 was enhanced as the incubation time increases [ Fig. 1(C) ]. Moreover, EGF-Rh was found to be co-localized with YFP-Cox7a2 in A431 cells [ Fig. 1(D) ].
In immunofluorescence staining, co-localization of mtHsp70-Cy3 with GFP-EGFR in PAE cells was observed [ Fig. 1(E) ], whereas there was no staining in the negative control without primary antibody (data not shown). Mitochondrial isolation, mitochondrial enrichment, and cytosol were detected by immunoblotting with antibody against mtHsp70, a protein specifically located on mitochondria but not detected in the cytosolic fraction.
Mitochondrial EGFR and endocytosis
Meanwhile, the mitochondrial fraction was found to be free of EEA-1, suggesting that the isolated mitochondria were not contaminated by the endosomal compartment [ Fig. 1(F) ]. All findings here indicated that EGFR has a mitochondrial location, and the receptor could move to mitochondria from the plasma membrane upon stimulation by its ligand.
EGFR mitochondrial localization is independent of endocytosis It has been suggested that a putative mitochondrialtargeting sequence might exist in EGFR [7] . Therefore, to map the motif in detail, EGFR mutant in which amino acids 646-660 were deleted and PAE cells expressing the mutated EGFR were generated [ Fig. 2(A) ]. In the internalization test, the receptor without 646-660 amino acids nearly failed to endocytosis upon the stimulation of EGF; yet, it had a quite amount of mitochondrial localization [ Fig. 2(B,C) ]. Compared with WT EGFR, it revealed that the mutated receptor had a less amount of mitochondrial location, suggesting that the amino acid sequence 646-660 may be partially responsible for mitochondrial translocation of EGFR. Nevertheless, the reduction in EGFR mutant without 646-660 amino acids in mitochondrial location is not well correlative with its decrease in the internalization Mitochondrial EGFR and endocytosis rate. These findings suggest that other unknown mechanism may also be responsible for the reduction in mitochondrial extent for mutant receptor.
To test whether the endocytosis is required for EGFR mitochondrial translocation, we analyzed PAE cells expressing a variety of mutant EGFR constructed previously [ Fig. 3(A) ] [23] . C'1022 mutant receptors displayed a reduced internalization rate [ Fig. 3(B) ] as well as a WT-like capability of transporting into mitochondria in the absence of EGFR stimulation [ Fig. 3(C) ]. Interestingly, treating cells with high concentration of EGF (100 ng/ml, 30 min) failed to cause a noticeable alteration of mitochondrial WT EGFR [ Fig. 3(D) ]. Receptors with defective endocytosis were more likely migrated into mitochondria upon challenge with the ligand [ Fig. 3(E,F) ]. Although C'1022 mutant and Y1068/86F mutated receptor had a similar internalization rate; yet, their basal level of mitochondrial EGFR was different in comparison with the receptors that have normal endocytosis. Thus, we assumed that endocytosis might not play a critical role in mediation of EGFR mitochondrial migration, especially under the stimulation of the ligand. All these findings suggest that endocytosis is not critical for EGFR mitochondrial translocation.
Mitochondrial EGFR is correlated with cell survival and cell death process Gefitinib is an inhibitor of EGFR kinase and is effective in the treatment of certain cancer cell types [19, 20] . To test its effect on mitochondrial EGFR, A431 cells were treated with gefitinib. The EGFR endocytosis was blocked after exposing the cells in 1 mM gefitinib for 2 h [Fig. 4(A) ], but no obvious effect on the receptor mitochondrial location was found (data not shown). Treatment with 1 mM gefitinib for 24 h did not markedly decrease the total amount of mitochondrial EGFR, but attenuated the amount Figure 3 EGFR mitochondrial localization is independent of its endocytosis (A) Schematic representation of EGFR mutants. WT EGFR is drawn with the extracellular, transmembrane (TM), intracellular domain (kinase and C-terminus), and main tyrosine phosphorylation sites (residues 992, 1068, 1086, 1148, and 1173). Mutant has C-terminal truncation of 164 amino acid residues (C'1022), and main tyrosines and kinase site mutation (Y1068/86F, Y1148/73F, 5M) are indicated. Internalization tests (B) and mitochondrial isolation (C-F) of WT and mutated receptors were performed as described in the 'Materials and Methods' section. Lysates of total homogenate (TH) and mitochondria (Mito) were immunoblotted with antibodies indicated. Densitometry was performed for quantification. The ratio of mitochondrial EGFR (M) to total EGFR (T) is presented below the blots. The ratios represent the results of three independent experiments.
Mitochondrial EGFR and endocytosis of PK-resistant mitochondrial EGFR [ Fig. 4(B) ] and the cell viability [ Fig. 4(C) ]. Extended treatment for 72 h with 1 mM gefitinib resulted in greater loss for both mitochondrial EGFR and viable cells [ Fig. 4(D,E) ]. Our findings indicate that gefitinib can inhibit cell viability by initially reducing content of mitochondrial EGFR or breaking balance of EGFR between inner and outer membrane of mitochondria. Thus, we assumed that mitochondrial EGFR might play a pivotal role in deciding cell fate following EGF or other agent challenge under certain condition. To detect whether mitochondrial EGFR were mediated by cell death program, we analyzed EGFR mitochondrial migration in cells treated with etoposide, a topoisomerase II inhibitor that induces apoptosis. Upon application of etoposide (20 mM) to A431 cells, cell viability was decreased as well as the amount of mitochondrial EGFR [ Fig. 4(F,G) ]. Given that EGFR was indeed on mitochondria, we further investigated the effects of EGF on this subset of receptors. In a previous study, it has been shown that treatment with EGF leads to the up-regulation of EGFR in mitochondria [7] . However, we found that the effect of the ligand on EGFR mitochondrial localization appeared to be cell-and mutant receptor type-dependent [ Fig. 3(E,F) ]. Cox7a2 was used as a marker of mitochondria. Surprisingly, when the amount of mitochondrial EGFR was decreased (in both cases of pEGFP-N1 vector and Cox7a2), apoptosis was increased [ Fig. 4(H,I) ]. Overexpression of Cox7a2 reduced mitochondrial EGFR to the basal level and resulted in relative resistance of these cells to EGF-induced apoptosis (200 ng/ml, 1 h). On the contrary, pEGFP-N1 vector-transfected cells had comparatively higher content of mitochondrial EGFR, and underwent apoptotic cell death upon stimulation by EGF. In the later case, EGF reduced the content of this subset of receptors [ Fig. 4(H) ]. This finding suggested that the initial amount of mitochondrial EGFR is correlated with the ligand-induced loss of cell viability. It has to be noted that we failed to detect an apparently cleavage of poly(ADP)-ribose polymerase, a hallmark of caspasedepended apoptosis (data not shown). Thus, EGF might Figure 4 Gefitinib markedly decreases mitochondrial EGFR and cell viability A431 cells were exposed to gefitinib (1 mM) for 2 h (A), 24 h (B), and 72 h (D), respectively, before carrying out the internalization assay and mitochondrial isolation as described in the 'Materials and Methods' section. With or without PK treatment, lysates of mitochondria, and TH were immunoblotted using indicated antibodies. The cell viability of A431 cells following exposure to gefitinib (1 mM) for 24 h (C) and 72 h (E), respectively, or 20 mM etoposide (G) was measured by MTT assay. (F) A431 cells were exposed to etoposide (20 mM, 24 h) prior to mitochondria separation. The ratio of mitochondrial EGFR (M) to total EGFR (T) is presented below the blots. After 24 h transient transfection of either pEGFP-N1 vector or Cox7a2, A431 cells were exposed to EGF (200 ng/ml) for 1 h before mitochondria isolation (H) and flow cytometry analysis (I). The ratios represent results of three independent experiments. PK, proteinase K; na, not available.
Mitochondrial EGFR and endocytosis induce a caspase-independent apoptosis under above condition.
Discussion
Data presented here confirmed the former report that there was a mitochondrial localization of EGFR [7] . In addition, by immune electron microscopy, we were able to consolidate the findings of immunofluorescence and subcellular fractionation about the location of EGFR within the organelles [8] . Surprisingly, mutant EGFR with a defective internalization rate exhibited a greater migration into mitochondria in the presence of the ligand. All these findings suggested that endocytosis is not a critical element for EGFR mitochondrial translocation at the basal level. The finding about the mutant receptor with the deletion of 646-660 amino acids has revealed that the putative mitochondrial-targeting sequence in EGFR is only partially responsible for the receptor mitochondrial migration [7] . It has to be noted that there is an inconsistency about basal amount of mitochondrial EGFR among the mutant receptors, even their internalization rates are very similar. Thus, we assumed that other unknown mechanisms rather than endocytosis are also implicated in the mediation of mitochondrial migration of those receptors.
EGFR autophosphorylation is critical for both endocytosis and signal transduction [1, 2] . Nevertheless, EGFR mitochondrial translocation was apparently unrelated to the receptors' tyrosine phosphorylation rate. In fact, in PAE-C'1022 cells (stably expressing mutated EGFR C'1022), the mutant EGFR, which lacks four main tyrosine sites in the C-terminus, still had a mitochondrial localization. Consistent with previous data, these findings ruled out that EGFR migrate into the mitochondria via direct interaction with Shc adaptor proteins [28, 29] , which is found to locate within the mitochondria.
At present, it is still unclear why EGF can only initiate programmed cells death in these cells overexpressing its receptors [9, 10] and that the overexpression of gene such as Bcl-xL prevent EGF-induced apoptosis [30] . From our investigation, we reasonably believe that, in cells like A431 overexpressing EGFR, maintaining an adequate quantity of mitochondrial EGFR is critical for cell survival, as EGFor etoposide-induced programmed cell death usually concurs a decline in mitochondrial EGFR. Moreover, unlike HeLa cells, A431 cells were unable to prevent the cell death by increasing the expression of anti-apoptotic genes, such as Bcl-xL. On contrary, EGF treatment led to a decline in the Bcl-xL expression level and mitochondrial accumulation of Bax (a pro-apoptotic gene) in these cells [30] . In the case of Bcl-xL expression, the prevention of cell death may be due to the loss of mitochondrial EGFR, as we observed a decreased content of this subset of receptors upon transfection with Bcl-xL (data not shown). Incidentally, the expression of Cox7a2 reduced mitochondrial EGFR to the basal level and was unresponsive to EGF stimulation. Also, Bcl-xL is able to seal the vacant left over by the loss of mitochondrial EGFR and keep the mitochondria to be integral and function normally. These findings suggested that an adequate quantity of mitochondrial EGFR can decide cell fate by locating on the inner and outer membrane of the organelles and destroying EGFR balance on these two membranes will do harm to cells [8] .
The inhibition of EGFR kinase activity by gefitinib can be effective in the treatment of certain cancer cell types [19, 20] . Our findings indicated that gefitinib can inhibit cell viability by initially reducing the content of mitochondrial EGFR or destroying the balance of EGFR between the inner and the outer membrane of mitochondria. Taken together, we assumed that it is the mitochondrial EGFR, not the total receptors, plays a pivotal role in deciding cell fate following EGF or other agent challenge under certain conditions. The present data should shed light on issues of clinical importance.
In conclusion, our findings not only rule out the possibility that the endocytosis plays a role in mediating EGFR mitochondrial localization, but also reveal a previously unknown mechanism of regulating cell viability by EGFR.
